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Introduction
Familial Mediterranean fever (FMF) is rarely reported in
patients from central and south-eastern European coun-
tries (CSEE). The reason for this might be that the pre-
valence of FMF in CSEE is exceedingly low or that the
disease is significantly under-recognized among local
physicians. Moreover, genetic testing is not available in
most of the countries in the region.
Objectives
The aim of this study was to assess the frequency of
MEFV gene mutations in periodic fever patients from
CSEE countries.
Methods
We analyzed clinical, laboratory and genetic data of
MEFV gene of all periodic fever patients who were fol-
lowed at the University Children’s Hospital Ljubljana
from the beginning of 2006 to the beginning of 2013. In
addition, free genetic testing was provided for suspected
FMF patients with periodic fevers from the countries of
the CSEE region. Genetic testing was performed in the
Genetic laboratory of the University Children’s Hospital
Ljubljana. All 10 exons and intron/exon regions of
MEFV gene were directly sequenced with ABI Prism
310 Genetic analyzer.
Results
In total, 156 periodic fever patients were tested for
MEFV gene mutations; 118 from Slovenia, 14 from
Czech Republic, 6 from Slovakia, 4 from Croatia, 4 from
Romania, 3 from Macedonia, 2 from Serbia, 2 from
Hungary, 2 from Latvia and 1 from Lithuania. 73% of
the populations were children under the age of 18,
mean age at diagnosis was 6.6 years. 27% were adult,
mean age at diagnosis was 46.4 years. 53% of patients
were female and 47% were male.
31 patients (20%) were found to have at least one muta-
tion. 22 patients have had one mutation only; Slovenia 9/
15, Czech Republic 7/8, Slovakia 1/3, Macedonia 2/2,
Latvia 1/1, Hungary 1/1 and Croatia 1/1. 8 patients have
had two mutations; Slovenia 6/15, Slovakia 1/3, Czech
Republic 1/8 and 1 patient from Slovakia has had 3 muta-
tions. Homozygous mutation was found only in one
patient from Czech Republic. 1 novel MEVF gene muta-
tion was identified (S730F) in patient from Slovenia.
12 different mutations were found. The 2 most
frequently found were M694V (27%) and K695R (22%),
followed by P369S (12%), R408Q (12%), I591T (7%),
E148Q (5%), E167D (2%), A289V (2%), F479L (2%),
V726A (2%), S730F (2%) and A744S (2%).
Conclusion
MEFV gene mutations were identified in 31/156 (20%)
patients with periodic fevers from CSEE countries. In order
to increase the number of positive results ofMEFV genetic
testing clinical criteria for FMF diagnosis should be
followed. We suspect that clinical manifestations of FMF
could be influenced by the regional environment. We are
planning to evaluate genotype-phenotype correlation in
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